#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12562	16S	1529	1529	99.8	16S.l6.c4.ctg.1	2066	603.4	0	.	n	.	0	C469T	SNP	469	469	C	703	703	T	737	T,C	345,324	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12562	16S	1529	1529	99.8	16S.l6.c4.ctg.1	2066	603.4	0	.	n	.	0	A1420G	SNP	1420	1420	A	1654	1654	G	646	G,A,T	595,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12562	16S	1529	1529	99.8	16S.l6.c4.ctg.1	2066	603.4	0	.	n	.	0	C1450T	SNP	1450	1450	C	1684	1684	T	613	T,C	569,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	12562	16S	1529	1529	99.8	16S.l6.c4.ctg.1	2066	603.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	783	C,T	730,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23426	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3555	656.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1683	1683	A	842	A	769	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23426	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3555	656.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2317	2317	C	739	C,A	678,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23426	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3555	656.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2943	2943	T	698	T,C	649,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23426	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3555	656.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2391	2391	A	780	A	717	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	27	1910	folP	852	852	99.88	folP.l6.c30.ctg.1	1461	130.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4982	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3441	144.3	1	SNP	p	S91F	0	.	.	271	273	TCC	696	698	TCC	185;184;184	T;C;C,A,T	171;171;169,1,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4982	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3441	144.3	1	SNP	p	D95G	0	.	.	283	285	GAC	708	710	GAC	182;178;177	G;A;C	168;165;167	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4982	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3441	144.3	1	SNP	p	D95N	0	.	.	283	285	GAC	708	710	GAC	182;178;177	G;A;C	168;165;167	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1548	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1238	124.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	425	427	ACC	207;208;207	A;C;C	185;192;191	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1548	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1238	124.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	623	625	CAC	185;183;183	C;A;C	177;171;173	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1548	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1238	124.1	0	.	p	.	0	E117K	NONSYN	349	351	GAA	659	661	AAA	190;189;188	A;A;A	175;175;171	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1548	mtrR	633	633	99.21	mtrR.l15.c30.ctg.1	1238	124.1	1	SNP	p	G45D	0	.	.	133	135	GGC	443	445	GGC	200;201;203	G;G;C	183;182;186	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	832	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	884	93.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1489	1491	ATC	190;190;189	A,G;T;C	178,1;176;175	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1642	1644	GCA	196;198;199	G;C;A,G	175;177;175,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2125	2127	ATT	200;201;202	A;T;T	179;180;184	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	1	SNP	p	D86N	0	.	.	256	258	GAC	595	597	GAC	246;246;249	G,A;A;C	224,1;221;229	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	1	SNP	p	S87R	0	.	.	259	261	AGT	598	600	AGT	246;245;247	A;G;T	223;222;225	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	1	SNP	p	S87W	0	.	.	259	261	AGT	598	600	AGT	246;245;247	A;G;T	223;222;225	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	1	SNP	p	S87I	0	.	.	259	261	AGT	598	600	AGT	246;245;247	A;G;T	223;222;225	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	4724	parC	2304	2304	99.7	parC.l6.c30.ctg.1	3012	156.4	1	SNP	p	S88P	0	.	.	262	264	TCC	601	603	TCC	244;243;245	T;C;C	220;219;224	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4114	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2631	155.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1474	1476	GGC	190;189;185	G;G;C	175;175;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1205	1207	GCA	191;189;189	G;C;A	171;168;173	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1208	1210	ATC	188;191;192	A;T;C	171;172;175	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1220	1222	GTG	192;193;194	G;T;G	173;172;175	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1220	1222	GTG	192;193;194	G;T;G	173;172;175	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1724	1726	ACC	191;192;193	A;C;C	171;174;179	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1778	1780	GCG	173;173;171	G;C,G;G	148;136,1;139	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1778	1780	GCG	173;173;171	G;C,G;G	148;136,1;139	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1901	1903	GGC	175;172;171	G;G;C	154;153;153	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1910	1912	GGC	173;170;167	G;G;C	152;148;148	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	3780	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2335	161.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1928	1930	CCG	151;150;147	C,G;C;G	117,2;118;115	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	5192	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3109	166.7	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1655	1657	CTG	185;187;187	C;T;G	172;173;172	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2134	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1814	117.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	544	544	C	168	C	153	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	T18M	NONSYN	52	54	ACG	190	192	ATG	206;206;207	A;T;G	190;190;187	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	565	567	CAA	231;233;234	C;A;A	209;210;212	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	E212D	NONSYN	634	636	GAA	772	774	GAT	203;199;195	G;A;T	196;192;190	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	H213S	NONSYN	637	639	CAT	775	777	AGT	198;197;194	A;G;T	193;191;188	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	V215A	NONSYN	643	645	GTT	781	783	GCT	189;187;188	G;C;T,C	184;183;183,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	S220T	NONSYN	658	660	AGC	796	798	ACT	180;181;182	A;C;T	171;174;175	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	R257M	NONSYN	769	771	AGG	907	909	ATG	240;237;237	A;T;G	224;222;219	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	R258S	NONSYN	772	774	AGG	910	912	AGC	240;234;230	A;G;C,G	223;216;214,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	A259G	NONSYN	775	777	GCT	913	915	GGT	230;228;229	G;G;T	214;215;214	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1027	1029	AAC	214;213;214	A;A;C	198;197;198	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2500	porB1b	1047	1047	98.57	porB1b.l15.c30.ctg.1	1317	185.3	1	SNP	p	G120K	0	.	.	358	360	GGC	496	498	GGC	211;206;210	G;G;C,T	195;190;189,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9632	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4908	195.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2078	2080	CAT	201;205;209	C;A;T	187;190;193	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	970	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1119	86.2	1	SNP	p	V57M	0	.	.	169	171	GTG	582	584	GTG	204;204;205	G;T;G	183;183;187	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
